Abstract: Provided are processes for the prevention or treatment of viral infection in a subject. Some aspects provide administration of a sphingoid compound, optionally sphingosine, an active ingredient that activates generation of a sphingoid base, optionally of sphingosine; or an active agent that inhibits the degradation of a sphingoid base, optionally of sphingosine, to a subject such as a human. By increasing the local concentration of sphingosine in a subject or an area of a subject to which the composition is administered such as the nose or interior of the nose or portion thereof, the ability of viruses to infect the subject or cells thereof is reduced thereby treating of preventing infection by the virus.

Abstract: A spirooxindole nanoformulation includes a proniosome loaded with a spirooxindole derivative.

Abstract: This invention provides reagents, methods and biochemical markers for identifying and providing therapeutic intervention for individuals with metabolic dysfunction, or individuals at risk for metabolic dysfunction.

Abstract: Described herein are materials and methods for inducing therapeutic hypothermia in a subject in need thereof.

Abstract: Provided are an emulsion structure for enhancing skin absorption and a method of preparing the same. According to a composition of an aspect of the present disclosure, due to a hexagonal structure that can mimic intercellular lipid ingredients of skin, the composition has excellent formulation safety and piezoelectric properties capable of generating a microcurrent, and accordingly, the composition is able to enhance skin absorption of a physiologically active substance without damaging the skin barrier.

Abstract: A skin cleansing agent containing the following components (A), (B), and (C): a particle (A) including (A1), (A2), and (A3), (A1) a water-holding oil agent in an amount of from 0.0001 to 13 mass % in the skin cleansing agent, (A2) a moisturizing agent in an amount of from 0.001 to 25 mass % in the skin cleansing agent, and (A3) a polymer; a surfactant (B); and water (C).

Abstract: This disclosure concerns fatty acid derivatives, pharmaceutical compositions comprising the fatty acid derivatives, and methods of using the fatty acid derivatives, for example, to treat inflammation, chronic itch, chronic pain, an autoimmune disorder, atherosclerosis, a skin disorder, arthritis, a neurodegenerative disorder, or a psychiatric disorder in a subject. In some embodiments, the fatty acid derivative is a compound, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, having a structure according to: wherein X is from 1-16 carbons in length, Z is aliphatic from 1-16 carbons in length, or is not present, Y is selected from: R1, R2, and R3 are independently hydrogen or lower alkyl, R4 is lower alkyl, hydroxyl, carboxyl, or amine, R5 is hydrogen, lower alkyl, or halide, R6 is hydroxyl or substituted thiol, and each R7 is independently hydrogen or fluoride or is not present and the adjacent carbons form alkyne.

Abstract: The disclosure relates to the treatment of primary and metastatic cancer using radiation. Specifically, the disclosure relates to methods providing for the selective accretion of cytoprotective agent in tissues and/or organs, sensitive to radiation that are adjacent to malignant tumors prior to radiation of the tumors at a dose that otherwise would be toxic to the tissues and/or organs, but are necessary to achieve ablative outcome on the tumors.

Abstract: An anti-inflammatory composition is disclosed. The anti-inflammatory composition is useful for a pharmaceutical composition or a cosmetic composition by not only having excellent stability on the skin and therefore being harmless to the human body, but also by controlling the expression of an inflammatory skin disease-related mediating factor and thereby exhibiting an excellent anti-inflammatory effect.

Abstract: Topical formulations containing erythropoietin (EPO), and also preferably fibronectin (FN), especially gel formulations, are used to accelerate wound healing, e.g., from a burn, compared to the healing process without such a formulation being applied. Methods of preparing the formulations are also provided.

Abstract: The present invention relates to a process for preparing an additive as a food supplement based on algae for birds and animals. It also describes the food additive obtained, formulated with seaweed extract, whey, malto-dextrin, proteins, amino acids, minerals, fiber, fat, hormones, and has a final powder form. In addition, the use of the food additive to increase the weight gain in animals, the weight gain in eggs of birds, and for the production of meat in birds and animals is described.

Abstract: The present invention has shown that not all salts of pyruvic acid enhance lung functions or enhance the synthesis of lung surfactants and that certain salts of pyruvic acid with the correct concentrations of calcium, phosphate and magnesium, are synergistic in their ability to enhance the synthesis of lung surfactants that will enhance lung alveoli functions, while decreasing coughing and lung tightness, and increasing oxygen saturation values to prevent hypoxemia. This patent demonstrates that the sodium pyruvate formula with calcium, phosphate and magnesium was superior over standard sodium pyruvate formula in saline alone in the removal of mucus, reduction of lung or sinus infections, and in reducing drug side effects and congestion.

Abstract: Provided are processes for the prevention or treatment of viral infection in a subject. Some aspects provide administration of a sphingoid compound, optionally sphingosine, an active ingredient that activates generation of a sphingoid base, optionally of sphingosine; or an active agent that inhibits the degradation of a sphingoid base, optionally of sphingosine, to a subject such as a human. By increasing the local concentration of sphingosine in a subject or an area of a subject to which the composition is administered such as the nose or interior of the nose or portion thereof, the ability of viruses to infect the subject or cells thereof is reduced thereby treating of preventing infection by the virus.

Abstract: A polishing pad for polishing a surface, material for a polishing pad and a method for manufacturing material for a polishing pad. A polishing pad has a backing layer and a polishing layer made of sheep wool fibres fixed onto a surface of the backing layer, wherein the polishing layer has loops made of sheep wool fibres.

Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and ?-(methylsulfonyl)alkylamine or ?-(methylsulfonyl)alkylamide. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering ?-(methylsulfonyl)alkylamine or ?-(methyl sulfonyl)alkylamide, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

Abstract: The present invention relates to method of treatment of hepatitis C using bufexamac or a derivative thereof. The methods of the present invention can be used in patients with hepatitis C administering bufexamac or a derivative thereof in combination with one or more anti-hepatitis C drugs.

Abstract: A personal product antimicrobial preservative composition for preservation of topical personal care formulations is provided and includes [A] one or more undecylenic acid derivatives depicted by Formula (I), [B] one or more octanoic acid derivatives depicted by Formula (II), and [C] 2-phenoxy ethanol or 2-ethyl hexyl glyceryl ether or mixture of these two ‘liquid alcohol ethers’; wherein, each of the two components [A] and [B] is present in the range of 5 to 20% by weight and together [A] and [B] constitute 10 to 30% by weight and the ‘liquid alcohol ether’, component [C], is present 70 to 90% by weight of the total preservative composition. A method for preserving personal care product from microbial attack is provided containing an aqueous phase comprising three component composition from about 0.5 to 2.5% by weight of the total personal care formulation.

Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and ?-(methylsulfonyl)alkylamine or ?-(methylsulfonyl)alkylamide. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering ?-(methylsulfonyl)alkylamine or ?-(methylsulfonyl)alkylamide, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

Abstract: Methods and compositions comprising N-acetylcysteine amide (NAC amide) and derivatives thereof are used in treatments and therapies for human and non-human mammalian diseases, disorders, conditions and pathologies. Pharmaceutically or physiologically acceptable compositions of NAC amide or derivatives thereof are administered alone, or in combination with other suitable agents, to reduce, prevent, or counteract oxidative stress and free radical oxidant formation and overproduction in cells and tissues, as well as to provide a new source of glutathione.

Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and ?-(methylsulfonyl)alkylamine or ?-(methylsulfonyl)alkylamide. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering ?-(methylsulfonyl)alkylamine or ?-(methylsulfonyl)alkylamide, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

Abstract: Provided is an oxidative reduction potential (ORP) water solution that is stable for at least twenty-four hours and methods of using the solution. The present invention provides a method of preventing or treating a condition in a patient, which method comprises administering a therapeutically effective amount of the ORP water solution. Additionally provided is a method of treating impaired or damaged tissue, which method comprises contacting the tissue with a therapeutically effective amount of the ORP water solution. Further provided is a method of disinfecting a surface, which method comprises contacting the surface with an anti-infective amount of the ORP water solution.

Abstract: The invention relates to a surfactant concentrate which contains at least one anionic surfactant, an N-methyl-N-acylglucamine, a solvent and optionally one or more additives. The invention also relates to a method for producing the surfactant concentrate. The invention further relates to a method for producing cosmetic, dermatological or pharmaceutical compositions.

Abstract: An inhibitor for tobacco axillary bud growth, the inhibitor containing one or more cell division inhibitors selected from pyridine-based compounds and benzamide-based compounds. This inhibitor may further include an aliphatic alcohol having 6 to 20 carbon atoms in combination with the one or more cell division inhibitors.

Abstract: The invention relates to a formulation comprising caprylic acid ethanolamide and/or capric acid ethanolamide in combination with an aluminium salt and to its use.

Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and ?-(methylsulfonyl)alkylamine or ?-(methylsulfonyl)alkylamide. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering ?-(methylsulfonyl)alkylamine or ?-(methylsulfonyl)alkylamide, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

Abstract: An esteramide compound of the following formula (I): R1OOC-A-CONR2R3??(I) is described, wherein: A is a covalent bond or a methylene group —CH2—; R1 is an optionally substituted, saturated or unsaturated aliphatic or cycloaliphatic hydrocarbon group including from 5 to 36 carbon atoms, R2 and R3, either identical or different, are groups selected from a hydrogen atom, and optionally substituted hydrocarbon groups, preferably including from 1 to 36 carbon atoms, and R2 and R3 not being simultaneously hydrogen atoms. Also described, are applications for using the esteramide compound, notably as a solvent.

Abstract: Disclosed is a novel transdermally absorbable preparation which enables the efficient, stable and long-term administration of a drug to a living body. More specifically, the transdermally absorbable preparation comprises: a laminate comprising an outer film, a drug-containing layer and a support layer laminated in this order from the side to be contacted with the skin; and a fixing means for fixing the laminate on the skin. In the transdermally absorbable preparation, the outer film is a drug-permeable polymer film that can control the release of the drug into the skin and is provided as a surface of the laminate which is to be contact with the skin.

Abstract: A therapy for renal diseases, in particular renal diseases, which develop in diabetic patients or patients who have been subjected to a treatment with an antitumor chemotherapy such as a platinum derivative and more generally cytotoxic drugs at renal level for treating of neoplastic diseases. More particularly, palmitoylethanolamide and diethanolamide of fumaric acid are used in the treatment of renal diseases, in particular those caused by dysmetabolic diseases or by toxic or chemotherapy agents, such as platinum derivatives. Palmitoylethanolamide is used preferably in micronized or ultra-micronized form. Diethanolamide of fumaric acid is used preferably in aqueous solution.

Abstract: A scleral lens is provided with a sodium channel blocker or a sodium channel modulator disposed in the pre-corneal tear film between the scleral lens and the cornea. This system can be used to deliver sodium channel blockers or a sodium channel modulators not currently used because of poor bioavailability. Methods of using this sodium channel blocker delivery system or a sodium channel modulator delivery system are also disclosed.

Abstract: Cosmetic compositions comprising calcium citrate and at least one N-acylated aminoalcohol according to formula (I). Provided is a method of treating aged skin, comprising topically applying to the aged skin a composition comprising a compound of Formula (I) in an amount effective to provide an anti-ageing effect. The compound of Formula (I) is used to prevent skin and/or to help to maintain or improve moisture retention and/or to fight against the signs of skin ageing. The N-acylated aminoalcohol of formula (I) acts as a ceramidase inhibitor. The combination of at least one compound of formula (I) and calcium citrate stimulates keratinocyte differentiation.

Abstract: A method for treating phytophotodermatitis including the steps of applying an isothiocyanate functional surfactant to an area affected by phytophotodermatitis, wherein said isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.

Abstract: Disclosed herein are ?-galactosylceramide (?-GalCer) analogs and compositions thereof, methods of activating invariant Natural Killer T (iNKT) cells using said analogs, methods of treating diseases by activating iNKT cells using said analogs, and combination therapy of said analogs.

Abstract: A method for inhibiting formation of adhesions following abdominal surgery which involves application of an anti-static fatty acid ethoxylated amide (Cocamide DEA) in a matrix that is placed in the peritoneal cavity at the conclusion of an abdominal surgery and which releases this anti-adhesive chemical over a predetermined time in a range up to seven days. Tests conducted on laboratory rats established that the method reduced the incidence of adhesions from 100 percent (100%) in a test model to near zero in the majority of treated animals. In an alternative embodiment, andrographalide was delivered via a pump with similar results. In still another embodiment, an effective amount of 50% phosphatidylchorene and propylene glycol was delivered, via a pump, into the abdominal cavity, again with similar results.

Abstract: The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug.

Abstract: A formulation comprising dexamphetamine and lys-dexamphetamine useful in the treatment of ADHD or fatigue.

Abstract: Provided herein are sphingolipid compounds that are useful for activating natural killer T cells. Also provided are methods for treating or preventing a disease or disorder that is treatable by activating the immune system by stimulating natural killer T cells. The compounds are therefore useful for treating or reducing the likelihood of occurrence of an immune diseases and disorders, such as autoimmune diseases or disorders. The compounds may also be used for treating or reducing the likelihood of occurrence of a microbial infection or for treating or reducing the likelihood of occurrence of a cancer in a subject by administering the sphingolipid compounds described herein.

Abstract: Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infection.

Abstract: An oil-in-water emulsion skin cosmetic composition comprising the following components (A), (B), (C), (D) and (E): (A) from 1 to 10% by mass of an oil agent which is liquid at 25° C., (B) from 1 to 6% by mass of an oil agent which is solid or semi-solid at 25° C., (C) from 0.7 to 3.5% by mass of linear alcohol having 12 to 22 carbon atoms, (D) from 0.2 to 1% by mass of at least one selected from the group consisting of an ionic surfactant and a nonionic surfactant having an HLB of 12.5 to 15, and (E) water, wherein the mass ratio of the component (B) to the component (A), (B)/(A), is from 0.3 to 1.0, and emulsion particles have a number-average particle diameter of 1.0 to 3.0 ?m.

Abstract: This invention relates to medicaments and their use in the alleviation of inflammation and pain in joints.

Abstract: The invention relates to a topical patch comprising a therapeutic compound-impermeable backing layer, a self-adhesive matrix based on polysiloxanes and containing capsaicin or a therapeutic compound analogous to capsaicin, and a protective film to be removed before use, in which the matrix contains liquid microreservoirs based on an amphiphilic solvent, in which the therapeutic compound is present in completely dissolved form and the concentration of the therapeutic compound in the microreservoir droplets is below the saturation concentration. The invention furthermore relates to a process for its production and its use in the treatment of neuropathic pain.

Abstract: A synergistic composition, or the use of that composition in the manufacture of a medicament, or a method of treatment including the use of that composition, for the treatment of hair loss and baldness, for combined, sequential or simultaneous administration, in any form, via any biological route. In its optimal embodiment the composition consists, in the form of a lotion: 1600-2400 IU/mL Vitamin A Palmitate, 0.64%-0.96% Thiamine Hydrochloride, 0.64%-0.96% Pyridoxine Hydrochloride, 4.8%-7.2% Niacinamide, 2.85%-5.2% D-Panthenol, 1.6%-2.4% L-Arginine, 3.6%-4.4% Methyl Sulphonyl Methane (MSM), 0.08%-0.12% Ginger Oil, 0.08%-0.12% Cinnamon Oil, 0.0996%-0.1494% Oleoresin Capsicum, 1.3%-1.95% Magnesium, 2.4%-3.6% Zinc, 0.192%-0.288% Manganese, 2.6%-3.9% Urea, 2.4%-3.6% Sodium Glycerophosphate, 4.8%-7.2% L-Lysine HCl, plus Preservatives, Co-solvent (Propylene Glycol), Fragrances, Anti-Oxidant, Cooling agent (Menthol), Emulsifier, and Vehicle (Purified water).

Abstract: Described herein are compositions and methods for treating or preventing a sexually transmitted infection in a subject

Abstract: Cannabionid receptor-2 inverse antagonists include compounds represented by Formula IV, or a pharmaceutically acceptable salt thereof: wherein: R1 and R2 are independently H, alkyl, or alkenyl; R3 is alkyl, alkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl; R4 and R5 are independently a bond, alkylenyl, or alkenylenyl; each R6 and R7 is independently selected from the group consisting of OH, F, Cl, Br, I, (C1-C6)alkyl, alkoxy, amino, COOH, CONH2, SO3H, PO3H2, CN, SH, NO2 and CF3; and p and q are independently 0, 1, 2, 3, 4, or 5. Such compounds may be used to treat osteoporosis or multiple myeloma.

Abstract: The present invention is directed to a method of inhibiting CD1d activation by administering a composition containing a moiety that blocks CD1d activation. Compositions of the invention are useful for the attenuation of CD1d-restricted immune responses, including treatment of skin disorders due to hyperactive immune responses (e.g., contact hypersensitivity), for systemic administration to attenuate ongoing immune responses, and to provide hypoallergenic cosmetic products including pharmaceutical, cosmetic, and skin care compositions. Preferably, these compositions are in a form intended for topical administration.

Abstract: The present invention provides a composition for controlling plant diseases having an excellent control efficacy on plant diseases. A composition for controlling plant diseases comprising an amide compound represented by a formula (I); wherein each of symbols are the same as defined in the Description; or salts thereof and at least one kind of compounds selected from the group (A) consisting of kresoxim-methyl, azoxystrobin, pyraclostrobin, picoxystrobin, enestrobin, trifloxystrobin, dimoxystrobin, fluoxastrobin, orysastrobin, famoxadone, fenamidone, metominostrobin, a compound represented by a formula (II) and pyribencarb: shows an excellent controlling efficacy on plant diseases.

Abstract: The present invention relates to an emulsified hydrogel composition and to a production method therefor, wherein, by incorporating between 20 and 30 percent by weight of a gelling solution and an emulsion obtained by mixing between 45 and 60 percent by weight of an aqueous component and between 15 and 30 percent by weight of an oil component, it is possible to simultaneously provide the skin with an aqueous fraction and an oil fraction, and it is possible to enhance functionality due to the inclusion of a high content of a dermatologically active component dissolved in the oil component.

Abstract: Disclosed is a compound having an acceleration effect on the secretion of human ?-defensin, LL-37, which is a human-derived anti-microbial peptide, a method for preparing same, and a composition for accelerating the secretion of anti-microbial peptide having same as an active ingredient, and the compound and the composition using same of the present invention enhance the anti-microbial effect and the immunity control effect that the anti-microbial peptide has in the body by accelerating the secretion of the anti-microbial peptide in the body.

Abstract: The present invention provides a ceramide lamella structure comprising a glucoside surfactant, a preparation method thereof, and a skin composition for external use containing the same. According to the skin preparation composition for external use of the present invention, phase stability is very excellent and a greater amount of ceramides can be stably formed according to the stability of ceramides using multilayered lamellar liquid crystals, thereby showing excellent skin moisturizing and skin barrier function repairing effects when applied to the skin.

Abstract: The present disclosure relates to nutritional compositions comprising a neurologic component, wherein, the neurologic component may promote brain and nervous system development and further provide neurological protection and repair. The neurologic component may include phosphatidylethanolamine, sphingomyelin, cytidine diphosphate-choline, ceramide, uridine, at least one ganglioside, and mixtures thereof. The disclosure further relates to methods of promoting brain and nervous system health by providing said nutritional compositions to target subjects, which includes pediatric subjects.

Abstract: Disclosed herein is a method for prolonging analgesic effect of a membrane permeable local anesthetic in a subject in need thereof. The method uses cinnamaldehyde as an adjuvant which, when administered prior to or simultaneously with the administration of a local anesthetic, prolongs the analgesic effect of the local anesthetic. Also disclosed herein is a method for providing analgesic effect in a subject in need thereof. The method uses cinnamaldehyde as an analgesic compound which, when administered alone to the subject in an analgesically effective amount, provides the analgesic effect.